Trinity Biotech, a commercial-stage biotech company focused on human diagnostics and diabetes management solutions, including wearable biosensors, has appointed Barclays Capital as its exclusive finan ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next ...

John Gillard, CEO of Trinity Biotech, emphasized that their patented technology is set to disrupt the CGM market, which is expected to surpass $20 billion by 2029. He highlighted the ergonomic ...

Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose ...

Shares of TRIB opened at $0.76 on Friday. Trinity Biotech has a twelve month low of $0.74 and a twelve month high of $3.55. The stock has a market cap of $13.72 million, a PE ratio of -0.34 and a ...